Q-omics provides the consensus-scored C10orf82 profile across patient tissues and cancer cell-line models. C10orf82 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C10orf82 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, C10orf82 RNA expression shows 15,671 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where C10orf82 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C10orf82 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C10orf82 survival associations across molecular data types. C10orf82 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C10orf82 RNA expression–survival associations across cancer types. High C10orf82 expression shows unfavorable associations in KIRC, CESC and LIHC, but favorable associations in BRCA, SCLC and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C10orf82 RNA expression.
This table summarizes C10orf82 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C10orf82. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C10orf82 shows lower tumor expression in KIRC, THCA, KIRP, KICH and PRAD and higher tumor expression in BRCA. The KIRC box plot shows higher C10orf82 RNA expression in normal versus tumor tissue (log2 FC = −1.191, t-test p < 0.001).
This table shows molecular features associated with C10orf82 in patient tissues and cancer cell lines. In patient samples, C10orf82 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C10orf82 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
